$WVE Q3 '26 Earnings Results & Recap
• Reported GAAP EPS of -$0.30 up 6.25% YoY
• Reported revenue of $13.16M up 72.93% YoY
• Wave Life Sciences expects current cash, cash equivalents, and marketable securities to fund operations into 3Q 2028; a $12M GSK milestone is expected in 4Q 2026 and is excluded from runway.